Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suresh Durgam

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Psychiatry|March 8, 2023
Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or HarmedLeslie Citrome, Suresh Durgam, John B Edwards, et al.
The Journal of Clinical Psychiatry|February 5, 2016
The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trialsLeslie Citrome, Suresh Durgam, Kaifeng Lu, et al.
Neuropsychiatric Disease and Treatment|December 17, 2016
Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trialsSuresh Durgam, Changzheng Chen, Carl P Gommoll, et al.
Depression and Anxiety|January 25, 2019
Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled studySuresh Durgam, Changzheng Chen, Raffaele Migliore, et al.
CNS Spectrums|September 29, 2025
Efficacy of Lumateperone in depression associated with bipolar II disorder: a pooled analysis of late-phase clinical trialsSuresh Durgam, Hassan Lakkis, Susan G Kozauer, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 1, 2015
Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trialsEduard Vieta, Suresh Durgam, Kaifeng Lu, et al.
Paediatric Drugs|April 11, 2018
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive DisorderSuresh Durgam, Changzheng Chen, Raffaele Migliore, et al.
International Clinical Psychopharmacology|December 15, 2015
Cariprazine in the treatment of schizophrenia: a proof-of-concept trialSuresh Durgam, Robert E Litman, Kelly Papadakis, et al.
Neuropsychiatric Disease and Treatment|July 7, 2016
Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studiesAnita H Clayton, Suresh Durgam, Xiongwen Tang, et al.
Journal of Affective Disorders|October 19, 2016
Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorderTerence A Ketter, Suresh Durgam, Ronald Landbloom, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Psychiatry|March 8, 2023
Lumateperone for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or HarmedLeslie Citrome, Suresh Durgam, John B Edwards, et al.
The Journal of Clinical Psychiatry|February 5, 2016
The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trialsLeslie Citrome, Suresh Durgam, Kaifeng Lu, et al.
Neuropsychiatric Disease and Treatment|December 17, 2016
Categorical improvements in disease severity in patients with major depressive disorder treated with vilazodone: post hoc analysis of four randomized, placebo-controlled trialsSuresh Durgam, Changzheng Chen, Carl P Gommoll, et al.
Depression and Anxiety|January 25, 2019
Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled studySuresh Durgam, Changzheng Chen, Raffaele Migliore, et al.
CNS Spectrums|September 29, 2025
Efficacy of Lumateperone in depression associated with bipolar II disorder: a pooled analysis of late-phase clinical trialsSuresh Durgam, Hassan Lakkis, Susan G Kozauer, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 1, 2015
Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trialsEduard Vieta, Suresh Durgam, Kaifeng Lu, et al.
Paediatric Drugs|April 11, 2018
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive DisorderSuresh Durgam, Changzheng Chen, Raffaele Migliore, et al.
International Clinical Psychopharmacology|December 15, 2015
Cariprazine in the treatment of schizophrenia: a proof-of-concept trialSuresh Durgam, Robert E Litman, Kelly Papadakis, et al.
Neuropsychiatric Disease and Treatment|July 7, 2016
Characterizing sexual function in patients with generalized anxiety disorder: a pooled analysis of three vilazodone studiesAnita H Clayton, Suresh Durgam, Xiongwen Tang, et al.
Journal of Affective Disorders|October 19, 2016
Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorderTerence A Ketter, Suresh Durgam, Ronald Landbloom, et al.
Pageof 6